14.3 Weight Reduction and Long-term Maintenance Study of WEGOVY Injection in Pediatric Patients Aged 12 Years and Older with Obesity Overview of Clinical Trial in Pediatric Patients WEGOVY injection was evaluated to reduce excess body weight in pediatric patients aged 12 years of age and older with obesity in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to 95th percentile standardized for age and sex (Study 10) (NCT#04102189)
"But if you're talking about being on it forever, then yeah, it could add up to that," she added
I followed up several times through email and their support system, and the communication was slow, vague, and honestly frustrating
Foods to Avoid While Taking Spironolactone Tablets Dietary considerations can play a crucial role in managing potential side effects of Spironolactone, particularly those related to potassium levels